Published Date：Mar.2021
Industry：Pharma & Healthcare
Pages：104 Table Number：125
Single User Price：￥3650.00
Enterprise User Price：￥5600.00
Summary As the world continues to deal with COVID-19, economies are moving into recession, under multiple adverse factors, the GDP of European and American countries in the second quarter suffered a historical contraction. At an annualized rate, the US GDP fell by 32.9% month on month, while the overall GDP of the euro zone fell by 12.1%. Moreover, the economic prospects of Europe and the United States in the third quarter under the epidemic situation are hardly optimistic. The resumption of work and production not only brought economic data back, but also triggered a rebound in the epidemic situation. At present, the United States is still the 'epicenter' of the global epidemic. The total number of confirmed cases has exceeded 4.8 million, and the epidemic situation in some European countries has also rebounded. Affected by this, more than 20 states in the United States have announced the suspension or withdrawal of part of the economic restart plan. Britain and Italy have also decided to extend the state of emergency. The rebound of the epidemic situation has posed considerable risks to the economic prospects of Europe and the United States. In the second quarter of this year, US GDP shrank by 9.5% on a month on month basis, or 32.9% at an annual rate, the largest decline since the 1940s. Data show that the sharp decline in personal consumption is the main drag on the U.S. GDP growth in the second quarter. Compared with the United States, Europe's economic contraction in the second quarter was smaller, but it was also the lowest on record, with Germany and France contracting more than 10%. According to the data released by the Federal Bureau of statistics, Germany's GDP fell by 10.1% in the second quarter after adjusting for prices, seasons and working days, the largest decline since the quarterly economic data were available in 1970. Thanks to the effective control and policy support of the new epidemic, China's economy rebounded sharply in the second quarter. The growth rate of manufacturing industry, which accounted for about 28% of GDP, rebounded sharply to 4.4% from the negative value in the first quarter. Chinese original equipment manufacturers (OEMs) and suppliers are ramping up production. And there are increased investments in digital footprints in manufacturing. OEMs in other parts of the world are offering incentives to drive sales. XYZResearch published a report for global Alpha-1 Antitrypsin Deficiency Augmentation Therapy market in this environment. In terms of revenue, this research report indicated that the global Alpha-1 Antitrypsin Deficiency Augmentation Therapy market was valued at USD XXX million in 2020, and it is expected to reach a value of USD XXX million by 2027, at a CAGR of XX % over the forecast period 2021-2027. Correspondingly, the forecast analysis of Alpha-1 Antitrypsin Deficiency Augmentation Therapy industry comprises of China, USA, Japan, India, Korea and South America, with the production and revenue data in each of the sub-segments. The Grifols aims at producing XX K Units Alpha-1 Antitrypsin Deficiency Augmentation Therapy in 2020, with XX % production to take place in global market, CSL accounts for a volume share of XX %. Regional Segmentation (Value; Revenue, USD Million, 2026-2027) of Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market by XYZResearch Include China EU USA Japan India Southeast Asia South America Competitive Analysis; Who are the Major Players in Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market? Grifols CSL Baxter Kamada Takeda Pharmaceutical Abeona Therapeutics ... Major Type of Alpha-1 Antitrypsin Deficiency Augmentation Therapy Covered in XYZResearch report: Alpha-1 proteinase inhibitor Bronchodilators Steroids Antibiotics Application Segments Covered in XYZResearch Market Hospital Pharmacy Retail Pharmacy Online Stores For any other requirements, please feel free to contact us and we will provide you customized report.
Table of Contents Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Analysis 2021, With Top Companies, Production, Revenue, Consumption, Price and Growth Rate 1 Market Scope 1.1 Product Details and Introduction 1.1.1 Alpha-1 proteinase inhibitor -Product Introduction and Major Manufacturers 1.1.2 Bronchodilators -Product Introduction and Major Manufacturers 1.1.3 Steroids -Product Introduction and Major Manufacturers 1.1.4 Antibiotics -Product Introduction and Major Manufacturers 1.2 Market Snapshot 1.2.1 Major Companies Overview 1.2.2 Market Concentration 1.2.3 Six-Year Compound Annual Growth Rate (CAGR) 2 Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Assessment, by Segmentation 2.1 Type Breakdown Estimates & Forecast, Sales Volume (2026-2027) 2.2 Type Breakdown Estimates & Forecast, Sales Value (2026-2027) 2.3 Application Breakdown Estimates & Forecast, by Application (2026-2027) 3 Regional Market Analysis 3.1 China Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market 3.1.1 Top Companies leading Alpha-1 Antitrypsin Deficiency Augmentation Therapy Development in China (2016-2021) 3.1.2 Sales Value of Major Company in China Market (2016-2021) 3.1.3 China Alpha-1 Antitrypsin Deficiency Augmentation Therapy Price (USD/Unit), by Type (2019-2020) 3.1.4 Sales in China Market, by Type (2026-2027) 3.2 EU Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market 3.2.1 Top Companies leading Alpha-1 Antitrypsin Deficiency Augmentation Therapy Development in EU (2016-2021) 3.2.2 Sales Value of Major Company in EU Market (2016-2021) 3.2.3 EU Alpha-1 Antitrypsin Deficiency Augmentation Therapy Price (USD/Unit), by Type (2019-2020) 3.2.4 Sales in EU Market, by Type (2026-2027) 3.3 USA Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market 3.3.1 Top Companies leading Alpha-1 Antitrypsin Deficiency Augmentation Therapy Development in USA (2016-2021) 3.3.2 Sales Value of Major Company in USA Market (2016-2021) 3.3.3 USA Alpha-1 Antitrypsin Deficiency Augmentation Therapy Price (USD/Unit), by Type (2019-2020) 3.3.4 Sales in USA Market, by Type (2026-2027) 3.4 Japan Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market 3.4.1 Top Companies leading Alpha-1 Antitrypsin Deficiency Augmentation Therapy Development in Japan (2016-2021) 3.4.2 Sales Value of Major Company in Japan Market (2016-2021) 3.4.3 Japan Alpha-1 Antitrypsin Deficiency Augmentation Therapy Price (USD/Unit), by Type (2019-2020) 3.4.4 Sales in Japan Market, by Type (2026-2027) 3.5 India Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market 3.5.1 Top Companies leading Alpha-1 Antitrypsin Deficiency Augmentation Therapy Development in India (2016-2021) 3.5.2 Sales Value of Major Company in India Market (2016-2021) 3.5.3 India Alpha-1 Antitrypsin Deficiency Augmentation Therapy Price (USD/Unit), by Type (2019-2020) 3.5.4 Sales in India Market, by Type (2026-2027) 3.6 Southeast Asia Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market 3.6.1 Top Companies leading Alpha-1 Antitrypsin Deficiency Augmentation Therapy Development in Southeast Asia (2016-2021) 3.6.2 Sales Value of Major Company in Southeast Asia Market (2016-2021) 3.6.3 Southeast Asia Alpha-1 Antitrypsin Deficiency Augmentation Therapy Price (USD/Unit), by Type (2019-2020) 3.6.4 Sales in Southeast Asia Market, by Type (2026-2027) 3.7 South America Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market 3.7.1 Top Companies leading Alpha-1 Antitrypsin Deficiency Augmentation Therapy Development in South America (2016-2021) 3.7.2 Sales Value of Major Company in South America Market (2016-2021) 3.7.3 South America Alpha-1 Antitrypsin Deficiency Augmentation Therapy Price (USD/Unit), by Type (2019-2020) 3.7.4 Sales in South America Market, by Type (2026-2027) 4 Value Chain (Impact of COVID-19) 4.1 Alpha-1 Antitrypsin Deficiency Augmentation Therapy Value Chain Analysis 4.1.1 Upstream 4.1.2 Downstream 4.2 COVID-19 Impact on Alpha-1 Antitrypsin Deficiency Augmentation Therapy Industry 4.2.1 Industrial Policy Issued Under the Epidemic Situation 4.3 Cost-Under the Epidemic Situation 4.3.1 Cost of Raw Material 4.4 Channel Analysis 4.4.1 Distribution Channel-Under the Epidemic Situation 4.4.2 Distributors 5 Regional Market Forecast (2021-2027) 5.1 Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Sales and Growth Rate (2021-2027) 5.2 Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Sales Value and Growth Rate (2021-2027) 6 Alpha-1 Antitrypsin Deficiency Augmentation Therapy Competitive Analysis 6.1 Grifols 6.1.1 Grifols Company Profiles 6.1.2 Grifols Product Introduction 6.1.3 Grifols Alpha-1 Antitrypsin Deficiency Augmentation Therapy Production, Revenue (2016-2021) 6.1.4 SWOT Analysis 6.2 CSL 6.2.1 CSL Company Profiles 6.2.2 CSL Product Introduction 6.2.3 CSL Alpha-1 Antitrypsin Deficiency Augmentation Therapy Production, Revenue (2016-2021) 6.2.4 SWOT Analysis 6.3 Baxter 6.3.1 Baxter Company Profiles 6.3.2 Baxter Product Introduction 6.3.3 Baxter Alpha-1 Antitrypsin Deficiency Augmentation Therapy Production, Revenue (2016-2021) 6.3.4 SWOT Analysis 6.4 Kamada 6.4.1 Kamada Company Profiles 6.4.2 Kamada Product Introduction 6.4.3 Kamada Alpha-1 Antitrypsin Deficiency Augmentation Therapy Production, Revenue (2016-2021) 6.4.4 SWOT Analysis 6.5 Takeda Pharmaceutical 6.5.1 Takeda Pharmaceutical Company Profiles 6.5.2 Takeda Pharmaceutical Product Introduction 6.5.3 Takeda Pharmaceutical Alpha-1 Antitrypsin Deficiency Augmentation Therapy Production, Revenue (2016-2021) 6.5.4 SWOT Analysis 6.6 Abeona Therapeutics 6.6.1 Abeona Therapeutics Company Profiles 6.6.2 Abeona Therapeutics Product Introduction 6.6.3 Abeona Therapeutics Alpha-1 Antitrypsin Deficiency Augmentation Therapy Production, Revenue (2016-2021) 6.6.4 SWOT Analysis 7 Conclusion
List of Tables and Figures Figure Product Introduction Table Production (K Units) and Revenue (Million USD) of Major Players (2016-2021) Figure Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Production Market Share of Top 5 Players Table CAGR of Major Market (2021-2027) Table CAGR in Terms of Production of Each Type (2026-2027) Table CAGR in Terms of Production of Each Application (2026-2027) Table Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Sales (K Unit) by Type (2026-2027) Figure Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Sales (K Unit) and Growth Rate (2026-2027) Figure Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Sales Market Share (%) by Type (2019 -2020) Table Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Sales Value (Million USD) by Type (2026-2027) Figure Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Sales Value (Million USD) and Growth Rate (2026-2027) Figure Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Sales Value Market Share (%) by Type (2019-2020) Table Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Sales (K Unit) by Application (2026-2027) Table China Alpha-1 Antitrypsin Deficiency Augmentation Therapy Sales (K Unit) of Major Company (2016-2021) Table China Alpha-1 Antitrypsin Deficiency Augmentation Therapy Sales Market Share of Major Company (2016-2021) Table China Alpha-1 Antitrypsin Deficiency Augmentation Therapy Sales Value (Million USD) of Major Company (2016-2021) Figure China Alpha-1 Antitrypsin Deficiency Augmentation Therapy Sales Value (Million USD) and Growth Rate (2016-2021) Table China Alpha-1 Antitrypsin Deficiency Augmentation Therapy Sales Value Share of Major Company (2016-2021) Table China Alpha-1 Antitrypsin Deficiency Augmentation Therapy Price (USD/Unit), by Type (2019-2020) Table China Alpha-1 Antitrypsin Deficiency Augmentation Therapy Sales (Unit) by Type (2026-2027) Figure China Alpha-1 Antitrypsin Deficiency Augmentation Therapy Sales (Unit) by Type (2026-2027) Table EU Alpha-1 Antitrypsin Deficiency Augmentation Therapy Sales (K Unit) of Major Company (2016-2021) Table EU Alpha-1 Antitrypsin Deficiency Augmentation Therapy Sales Market Share of Major Company (2016-2021) Table EU Alpha-1 Antitrypsin Deficiency Augmentation Therapy Sales Value (Million USD) of Major Company (2016-2021) Figure EU Alpha-1 Antitrypsin Deficiency Augmentation Therapy Sales Value (Million USD) and Growth Rate (2016-2021) Table EU Alpha-1 Antitrypsin Deficiency Augmentation Therapy Sales Value Share of Major Company (2016-2021) Table EU Alpha-1 Antitrypsin Deficiency Augmentation Therapy Price (USD/Unit), by Type (2019-2020) Table EU Alpha-1 Antitrypsin Deficiency Augmentation Therapy Sales (Unit) by Type (2026-2027) Figure EU Alpha-1 Antitrypsin Deficiency Augmentation Therapy Sales (Unit) by Type (2026-2027) Table USA Alpha-1 Antitrypsin Deficiency Augmentation Therapy Sales (K Unit) of Major Company (2016-2021) Table USA Alpha-1 Antitrypsin Deficiency Augmentation Therapy Sales Market Share of Major Company (2016-2021) Table USA Alpha-1 Antitrypsin Deficiency Augmentation Therapy Sales Value (Million USD) of Major Company (2016-2021) Figure USA Alpha-1 Antitrypsin Deficiency Augmentation Therapy Sales Value (Million USD) and Growth Rate (2016-2021) Table USA Alpha-1 Antitrypsin Deficiency Augmentation Therapy Sales Value Share of Major Company (2016-2021) Table USA Alpha-1 Antitrypsin Deficiency Augmentation Therapy Price (USD/Unit), by Type (2019-2020) Table USA Alpha-1 Antitrypsin Deficiency Augmentation Therapy Sales (Unit) by Type (2026-2027) Figure USA Alpha-1 Antitrypsin Deficiency Augmentation Therapy Sales (Unit) by Type (2026-2027) Table Japan Alpha-1 Antitrypsin Deficiency Augmentation Therapy Sales (K Unit) of Major Company (2016-2021) Table Japan Alpha-1 Antitrypsin Deficiency Augmentation Therapy Sales Market Share of Major Company (2016-2021) Table Japan Alpha-1 Antitrypsin Deficiency Augmentation Therapy Sales Value (Million USD) of Major Company (2016-2021) Figure Japan Alpha-1 Antitrypsin Deficiency Augmentation Therapy Sales Value (Million USD) and Growth Rate (2016-2021) Table Japan Alpha-1 Antitrypsin Deficiency Augmentation Therapy Sales Value Share of Major Company (2016-2021) Table Japan Alpha-1 Antitrypsin Deficiency Augmentation Therapy Price (USD/Unit), by Type (2019-2020) Table Japan Alpha-1 Antitrypsin Deficiency Augmentation Therapy Sales (Unit) by Type (2026-2027) Figure Japan Alpha-1 Antitrypsin Deficiency Augmentation Therapy Sales (Unit) by Type (2026-2027) Table India Alpha-1 Antitrypsin Deficiency Augmentation Therapy Sales (K Unit) of Major Company (2016-2021) Table India Alpha-1 Antitrypsin Deficiency Augmentation Therapy Sales Market Share of Major Company (2016-2021) Table India Alpha-1 Antitrypsin Deficiency Augmentation Therapy Sales Value (Million USD) of Major Company (2016-2021) Figure India Alpha-1 Antitrypsin Deficiency Augmentation Therapy Sales Value (Million USD) and Growth Rate (2016-2021) Table India Alpha-1 Antitrypsin Deficiency Augmentation Therapy Sales Value Share of Major Company (2016-2021) Table India Alpha-1 Antitrypsin Deficiency Augmentation Therapy Price (USD/Unit), by Type (2019-2020) Table India Alpha-1 Antitrypsin Deficiency Augmentation Therapy Sales (Unit) by Type (2026-2027) Figure India Alpha-1 Antitrypsin Deficiency Augmentation Therapy Sales (Unit) by Type (2026-2027) Table Southeast Asia Alpha-1 Antitrypsin Deficiency Augmentation Therapy Sales (K Unit) of Major Company (2016-2021) Table Southeast Asia Alpha-1 Antitrypsin Deficiency Augmentation Therapy Sales Market Share of Major Company (2016-2021) Table Southeast Asia Alpha-1 Antitrypsin Deficiency Augmentation Therapy Sales Value (Million USD) of Major Company (2016-2021) Figure Southeast Asia Alpha-1 Antitrypsin Deficiency Augmentation Therapy Sales Value (Million USD) and Growth Rate (2016-2021) Table Southeast Asia Alpha-1 Antitrypsin Deficiency Augmentation Therapy Sales Value Share of Major Company (2016-2021) Table Southeast Asia Alpha-1 Antitrypsin Deficiency Augmentation Therapy Price (USD/Unit), by Type (2019-2020) Table Southeast Asia Alpha-1 Antitrypsin Deficiency Augmentation Therapy Sales (Unit) by Type (2026-2027) Figure Southeast Asia Alpha-1 Antitrypsin Deficiency Augmentation Therapy Sales (Unit) by Type (2026-2027) Table South America Alpha-1 Antitrypsin Deficiency Augmentation Therapy Sales (K Unit) of Major Company (2016-2021) Table South America Alpha-1 Antitrypsin Deficiency Augmentation Therapy Sales Market Share of Major Company (2016-2021) Table South America Alpha-1 Antitrypsin Deficiency Augmentation Therapy Sales Value (Million USD) of Major Company (2016-2021) Figure South America Alpha-1 Antitrypsin Deficiency Augmentation Therapy Sales Value (Million USD) and Growth Rate (2016-2021) Table South America Alpha-1 Antitrypsin Deficiency Augmentation Therapy Sales Value Share of Major Company (2016-2021) Table South America Alpha-1 Antitrypsin Deficiency Augmentation Therapy Price (USD/Unit), by Type (2019-2020) Table South America Alpha-1 Antitrypsin Deficiency Augmentation Therapy Sales (Unit) by Type (2026-2027) Figure South America Alpha-1 Antitrypsin Deficiency Augmentation Therapy Sales (Unit) by Type (2026-2027) Figure Value Chain Structure of Alpha-1 Antitrypsin Deficiency Augmentation Therapy Table Value Chain Table Key Suppliers of Raw Material/Components Table Key Downstream Customer in Each Application Field Table Industry News List of Alpha-1 Antitrypsin Deficiency Augmentation Therapy Figure Cost Structure of Alpha-1 Antitrypsin Deficiency Augmentation Therapy in 2020 Table Distributors/Traders List Table Regional Market Sales (K Unit) (2021-2027) Table Regional Market Sales Share (2021-2027) Figure Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Sales (Unit), Growth Rate & Market Share (2021-2027) Table Regional Market Sales Value (Million USD) (2021-2027) Table Regional Market Sales Value Share (2021-2027) Figure Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Sales Value (Million USD), Growth Rate & Market Share (2021-2027) Table Grifols Profiles Table Grifols Alpha-1 Antitrypsin Deficiency Augmentation Therapy Product Introduction Table Grifols Alpha-1 Antitrypsin Deficiency Augmentation Therapy Sales (Unit), Sales Value (Million USD), Price (USD/Unit) and Gross Profit (2016-2021) Figure Grifols SWOT Analysis Table CSL Profiles Table CSL Alpha-1 Antitrypsin Deficiency Augmentation Therapy Product Introduction Table CSL Alpha-1 Antitrypsin Deficiency Augmentation Therapy Sales (Unit), Sales Value (Million USD), Price (USD/Unit) and Gross Profit (2016-2021) Figure CSL SWOT Analysis Table Baxter Profiles Table Baxter Alpha-1 Antitrypsin Deficiency Augmentation Therapy Product Introduction Table Baxter Alpha-1 Antitrypsin Deficiency Augmentation Therapy Sales (Unit), Sales Value (Million USD), Price (USD/Unit) and Gross Profit (2016-2021) Figure Baxter SWOT Analysis Table Kamada Profiles Table Kamada Alpha-1 Antitrypsin Deficiency Augmentation Therapy Product Introduction Table Kamada Alpha-1 Antitrypsin Deficiency Augmentation Therapy Sales (Unit), Sales Value (Million USD), Price (USD/Unit) and Gross Profit (2016-2021) Figure Kamada SWOT Analysis Table Takeda Pharmaceutical Profiles Table Takeda Pharmaceutical Alpha-1 Antitrypsin Deficiency Augmentation Therapy Product Introduction Table Takeda Pharmaceutical Alpha-1 Antitrypsin Deficiency Augmentation Therapy Sales (Unit), Sales Value (Million USD), Price (USD/Unit) and Gross Profit (2016-2021) Figure Takeda Pharmaceutical SWOT Analysis Table Abeona Therapeutics Profiles Table Abeona Therapeutics Alpha-1 Antitrypsin Deficiency Augmentation Therapy Product Introduction Table Abeona Therapeutics Alpha-1 Antitrypsin Deficiency Augmentation Therapy Sales (Unit), Sales Value (Million USD), Price (USD/Unit) and Gross Profit (2016-2021)
